Document is current

Article History

Received: 29 September 2023

Accepted: 27 December 2023

First Online: 16 January 2024

Declarations

:

: Procedures were implemented following the ethical standards of the Declaration of Helsinki, and the protocol was approved by the institutional ethics review board (Research Ethics Committee with medicines, CEIm Institute of Health Pere Virgili, Ref.164/2019).

: Not applicable.

: M.Boada has consulted for Araclon, Avid, Grifols, Lilly, Nutricia, Roche, Eisai, and Servier. She has received fees from lectures and funds for research from Araclon, Biogen, Grifols, Nutricia, Roche, and Servier. She reports grants/research funding from Abbvie, Araclon, Biogen Research Limited, Bioiberica, Grifols, Lilly, S.A, Merck Sharp & Dohme, Kyowa Hakko Kirin, Laboratorios Servier, Nutricia SRL, Oryzon Genomics, Piramal Imaging Limited, Roche Pharma SA, and Schwabe Farma Iberica SLU, all outside the submitted work. She has not received personal compensation from these organizations. A.R. is a member of the scientific advisory board of Landsteiner Genmed and Grifols SA. A.R. has stocks in Landsteiner Genmed. He reports grants/research funding from Araclon and Grifols. M.M. has consulted for F. Hoffmann-La Roche Ltd. The rest of authors declare that they have no competing interests.